12 results

• JAK Inhibitors Could Increase Cancer Risks by as Much as 40%: Study

  July 3, 2025

  Irvin Jackson

  A new study reinforces previous concerns that arthritis and autoimmune disease treatments like Xeljanz may be linked to an increased risk of cancer.

• Side Effects of Xeljanz, Rinvoq and Similar Drugs May Increase Risk of Acne: Study

  November 8, 2023

  Martha Garcia

  A new study links Xeljanz, Rinvoq and similar drugs to an increased risk of developing acne.

• Cancer Risk with Xeljanz, Other JAK Inhibitors Higher Than Among Users of Older TNF Inhibitors

  May 1, 2023

  Russell Maas

• Rinvoq Lawsuit Filed Against AbbVie By Investors Over Failure to Disclose Safety Concerns

  April 14, 2022

  Irvin Jackson

  AbbVie faces a class action lawsuit by investors who say the company mislead them about the safety of Rinvoq before new warning labels for cancer and heart problems were added.

• Rinvoq Approved As Atopic Dermatitis Treatment Despite Heart, Cancer Risks

  January 19, 2022

  Irvin Jackson

  The FDA has approved Rinvoq for the treatment of atopic dermatitis despite cancer and heart problem fears.

• Despite Side Effects of Xeljanz and Rinvoq, FDA Still Approves New Indications After Updated Warnings

  December 16, 2021

  Irvin Jackson

  The FDA has granted new approvals for rheumatoid arthritis drugs Xeljanz and Rinvoq despite concerns over heart, cancer and blood clot side effects.

• Rinvoq Warning Label Updated to Add Cancer and Heart Risks Seen With Xeljanz Side Effects

  December 6, 2021

  Irvin Jackson

  Rinvoq will now carry label warnings on cancer and heart risks which were first discovered through a study of Xeljanz side effects.

• Eli Lilly-Funded Study Claims Side Effects of Olumiant Do Not Warrant Same Adverse Label Warnings as Xeljanz

  November 16, 2021

  Irvin Jackson

  A new study announced by Eli Lilly appears to suggest Olumiant, a rheumatoid arthritis drug, does not need the same label warnings for heart problems as Xeljanz, it's competitor.

• Xeljanz Heart Risks May Be Similar Across Other JAK Inhibitors Like Rinvoq, Oluminant: Study

  November 12, 2021

  Irvin Jackson

  A new study suggests the risk of heart problems linked to Xeljanz is similar across all other rheumatoid arthritis drugs belonging to the same class of medications.

• Xeljanz FDA Label Warning Update Adds Information About Risk of Cancer, Blood Clots and Heart Side Effects

  September 2, 2021

  Irvin Jackson

  The FDA is requiring new label warnings for Xeljanz and similar drugs, following a review which revealed links between increased risks of heart attacks, strokes, blood clots, and lymphomas, as well as an increased risk of lung cancer for current or former smokers.